High response rates reported by GSK and iTeos at the 2024 European Society for Medical Oncology Congress offer a ray of light ...

The published belrestotug/dostarlimab data is still too immature to prove the combination’s capability to disrupt the NSCLC ...

The results of the GALAXIES Lung-02 study reported at the ESMO congress in Barcelona showed that the drug – added to GSK's PD ...

The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer ...

At the European Society for Medical Oncology (ESMO) Congress 2024, GSK and iTeos finally provided the first data reveal of their TIGIT inhibitor, belrestotug, in combination with Jemperli ...

Teos Therapeutics' belrestotug shows promising response rates in lung cancer trials. Read more to see why I'm bullish on ITOS ...

The combination of belrestotug and dostarlimab significantly improved response rates in patients with previously untreated ...

Kristen Foreman shares the first symptoms she experienced before doctors discovered a mass. It was ovarian and endometrial ...

According to Biospace.com "The solid tumors market size reached a value of US$ 170.3 Billion in 2023. Looking forward, the market is expected to reach US$ 375.4 Billion by 2034, exhibiting a growth ...

AstraZeneca (Nasdaq: AZN) Roche (OTCQX: RHHBY) September 17, 2024 - Investorideas , a go-to investing platform, releases the first of a two-part series looking at news and developments for the ...

All three were in study arms involving ITeos’ drug; none of the 32 trial participants given only GSK’s therapy, Jemperli, died from treatment-related side effects. This kind of inflammatory reaction ...